Pevonedistat
As of the edition of 20 October 2026, Pevonedistat is a small molecule: stopped in 2025; acts on NAE1 and UBA3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 41, 10 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Digestive system; Heart and blood vessels; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 22 | 18 | 1 | 3 |
| Phase 2 | 15 | 4 | 4 | 7 |
| Phase 3 | 3 | 1 | 2 | 0 |
| All trials | 41 |